Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03923426
Previous Study | Return to List | Next Study

Real-World Observational Study Of Zavicefta to Characterize Use Patterns (EZTEAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03923426
Recruitment Status : Recruiting
First Posted : April 22, 2019
Last Update Posted : February 20, 2020
Sponsor:
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date April 18, 2019
First Posted Date April 22, 2019
Last Update Posted Date February 20, 2020
Actual Study Start Date November 27, 2018
Estimated Primary Completion Date March 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: May 30, 2019)
  • Proportion of patients for each indication and reason for use of ceftazidime-avibactam [ Time Frame: Drug initiation until 60 days post-hospital discharge ]
  • Proportion of patients for each usage pattern of ceftazidime-avibactam. [ Time Frame: Drug initiation until 60 days post-hospital discharge ]
    Usage patterns including treatment line, dose, frequency of dose, duration, and polytherapy regimens.
  • Proportion of patients treated with ceftazidime-avibactam with defined microbiologic evidence of infection. [ Time Frame: Drug initiation until 60 days post-hospital discharge ]
  • Proportion of patients treated with ceftazidime-avibactam with a defined source of infection. [ Time Frame: Drug initiation until 60 days post-hospital discharge ]
    Sources of infection including community-acquired infection (CAI), hospital-acquired infection (HAI) and healthcare-associated infection (HCAI).
Original Primary Outcome Measures
 (submitted: April 18, 2019)
  • Proportion of patients for each indication and reason for use of ceftazidime-avibactam [ Time Frame: Drug initiation until 60 days post-hospital discharge ]
  • Poportion of patients for each usage pattern of ceftazidime-avibactam. [ Time Frame: Drug initiation until 60 days post-hospital discharge ]
    Usage patterns including treatment line, dose, frequency of dose, duration, and polytherapy regimens.
  • Proportion of patients treated with ceftazidime-avibactam with defined microbiologic evidence of infection. [ Time Frame: Drug initiation until 60 days post-hospital discharge ]
  • Proportion of patients treated with ceftazidime-avibactam with a defined source of infection. [ Time Frame: Drug initiation until 60 days post-hospital discharge ]
    Sources of infection including community-acquired infection (CAI), hospital-acquired infection (HAI) and healthcare-associated infection (HCAI).
Change History
Current Secondary Outcome Measures
 (submitted: April 18, 2019)
  • Proportion of patients and their respective clinical outcomes of treatment with ceftazidime-avibactam [ Time Frame: Drug initiation until 60 days post-hospital discharge ]
  • Proportion of patients and their respective safety outcomes of treatment with ceftazidime-avibactam [ Time Frame: Drug initiation until 60 days post-hospital discharge ]
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Real-World Observational Study Of Zavicefta to Characterize Use Patterns
Official Title REAL-WORLD OBSERVATIONAL STUDY OF ZAVICEFTA (REGISTERED) (CEFTAZIDIME-AVIBACTAM) TO CHARACTERIZE USE PATTERNS, EFFECTIVENESS AND SAFETY - EZTEAM STUDY
Brief Summary This is a non-interventional medical chart review study aiming to examine the treatment patterns, effectiveness, and safety of ceftazidime-avibactam in approximately 8 countries (including but not limited to Austria, France, Germany, Greece, Italy, Spain, United Kingdom, Russia), with possible expansion to other countries as ceftazidime-avibactam is launched. Eligible patients are adults who have been treated with ceftazidime-avibactam in routine practice at participating sites since 01 January, 2018 onwards or since the date of launch in the country if it is posterior to 01 January, 2018. As this is an observational study, patients will be treated based on the standard of care at the discretion of their physician. No drugs will be supplied for this study and patients will receive treatment through standard local practice.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Hospitalized patients with ≥72 hours of exposure to ceftazidime-avibactam at 42 European sites. Patients will be identified over a 12-month period and information about treatment will be abstracted from medical records after treatment completion. Patients will be followed from ceftazidime-avibactam initiation until 60 days post hospital discharge, mortality, withdrawal, or loss-to-follow-up, whichever occurs first.
Condition Infection
Intervention Other: Zavicefta Treatment
Non-interventional - Retrospective Chart Review
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: December 11, 2019)
1030
Original Estimated Enrollment
 (submitted: April 18, 2019)
630
Estimated Study Completion Date March 1, 2022
Estimated Primary Completion Date March 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Hospitalized patient ≥18 years old or considered an adult in accordance with the age of majority in the participant's country of residence at the time of treatment with ceftazidime-avibactam.
  2. Patient received ≥1 dose of ceftazidime-avibactam in routine practice at participating site since 01 January, 2018 onwards or since the date of launch in the country if it is after 01 January, 2018.
  3. Patient underwent microbiologic sampling ≤5 days before the initiation of ceftazidime-avibactam (irrespective of results and actual bacteriological identification).
  4. Patient has all required essential data elements which include:

    1. Start and stop dates of ceftazidime-avibactam,
    2. Start and stop dates of prior antibiotic therapy used for the index infection,
    3. Type of combined antibiotic therapy (if applicable) and start and stop dates of any antibiotic combined with ceftazidime-avibactam.
  5. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study where required by local regulations.

Exclusion Criteria:

Patients must not meet any of the following exclusion criteria to be eligible:

  1. The patient is enrolled in any clinical trial of an investigational product. Patients who are enrolled in non-interventional studies (NISs) (e.g. registries) are eligible for inclusion.
  2. The patient has received ceftazidime-avibactam in a compassionate care program setting.
  3. The patient was exposed to ceftazidime-avibactam before use for the index infection.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com
Listed Location Countries France
Removed Location Countries  
 
Administrative Information
NCT Number NCT03923426
Other Study ID Numbers C3591031
EZTEAM STUDY ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date February 2020